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Hospitalizations Associated with Pneumococcal Infection within the
Medicare Population Among Vaccinated and Non-vaccinated Patients
Silky F. Webb, Pharm.D.
ABSTRACT
Background: Streptococcus pneumoniae is the primary causative agent of pneumonia in older
adults. Vaccination is the only tool to protect against pneumococcal infection; however,
vaccination rates remain far below the Healthy People 2010 objective of 90% coverage. The
number one reason for such low rates is attributed to controversy over the protective efficacy of
the vaccine in preventing nonbacteremic pneumonia (eg, community-acquired pneumonia [CAP]).
Objectives: The primary objectives of this study were to assess the incidence of pneumonia,
pneumonia requiring hospitalization, and pneumonia hospitalization costs.
Methods: In this retrospective cohort study of Medicare beneficiaries aged 65 years in 2003,
subjects were selected based on exposure status. Exposure was defined as receipt of the 23valent pneumococcal polysaccharide vaccine (PPV23). Vaccinated persons were then matched
1:1 on gender and the presence of any comorbidity to unvaccinated persons. Subjects were
followed up for 1 year (January 1, 2004 through December 31, 2004). The primary outcomes
were pneumonia, pneumonia requiring hospitalization, and hospitalization costs. MantelHaenszel chi-square or logit was used to estimate the relative risk (RR) associated with
vaccination and each outcome and Proc Ttest was used to test the difference between mean
hospital costs of the vaccinated and non-vaccinated.
Results: During the follow-up period, 443 patients were diagnosed with pneumonia; 266 had
previously been vaccinated and 177 had no documented receipt of prior vaccination. Results of
the Chi-square analysis revealed a significant association between vaccination and the risk of
pneumonia, as the vaccinated were 50% more likely to develop pneumonia than were the nonvaccinated (Adjusted RR: 1.50; 95% CI: 1.25, 1.81). Approximately 67% of patients diagnosed
with pneumonia required hospitalization; of which, 183 were previously vaccinated and 115 had
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no documented receipt of prior vaccination. There was no association between vaccination and
risk of pneumonia requiring hospitalization (P value 0.4001). However, the vaccine was
associated with a significant reduction in hospital costs (P value 0.004).
Conclusions: The results of this study suggest that use of the vaccine may be associated with
cost savings due to a reduction in hospitalization.
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CHAPTER ONE
Introduction
Pneumococcal infection is a major source of morbidity and mortality in older adults over
age 65 years (Loeb, 2003). The primary causative agent of pneumococcal infection is
Streptococcus pneumoniae (CDC, 2006; Kupronis et al, 2003; Loeb, 2003).

Upon colonizing the

respiratory tract, S. pneumoniae can cause disseminated invasive infections, including
bacteremia/septicemia and meningitis; pneumonia and other lower respiratory tract infections;
and upper respiratory tract infections, including otitis media and sinusitis (DHHS, 1997). In
adults, 60% to 80% of pneumococcal bacteremia is associated with pneumonia (DHHS, 1997).
Adults older than 65 years are at a particularly higher risk for S. pneumoniae colonization due to
their advanced age, frequent presence of chronic illnesses, and institutionalism (ie, residence
within a long term care facility [LTCF]). In the United States (U.S.) and Canada, it is estimated
that between 5,000 and 30,000 cases of pneumococcal infection per annum occur in elderly
patients (Butler et al, 1999). Case-fatality rates in this population range from 30% to 40% (CDC,
2006; Kupronis et al, 2003).
Nonbacteremic pneumonia, the most common manifestation of pneumococcal infection
among the elderly (Jackson et al, 2003), exerts a great burden on the individual and society (De
Graeve et al, 2004). Hospitalization due to nonbacteremic community-acquired pneumonia
(CAP) in the U.S. has been estimated to range from $7,000 to $8,000 per admission or $4 million
per 100,000 population, accounting for approximately 90% of the total cost to treat nonbacteremic
CAP (De Graeve et al, 2004).
There are currently two 23-valent pneumococcal polysaccharide vaccines in the U.S.;
®

manufactured by Merck and Company, Inc. (Pneumovax 23) and Lederle Laboratories (Pnu®

Immune 23). In late 1983, the reformulated 23-valent vaccine replaced the 14-valent vaccine.
The 23 serotypes represented in the vaccine cause 85% of all invasive infections (DHHS, 1997).
The pneumococcal vaccine is recommended for those individuals at high risk for infection; this
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includes individuals older than 65 years, residents of LTCFs, and individuals with multiple
comorbidities and chronic conditions (DHHS, 1997). Unlike the influenza vaccine which is
recommended yearly, the pneumococcal vaccine has been recommended as a once in a lifetime
injection. Revaccination is recommended for those persons aged 65 years who received their
primary vaccination ≥5 years previously (DHHS, 1997).
One of the national Healthy People 2010 objectives is to achieve 90% pneumococcal
vaccination coverage among residents of LTCFs and older adults greater than 65 years (DHHS,
2000). Based upon the latest estimates from the Centers for Disease Control and Prevention
(CDC), vaccination rates remain far below this goal as only 49.9% of those aged 65 to 74 years
and 60.9% of those 75 years and older report ever being vaccinated (CDC, 2001b). One reason
for low immunization rates may be continued controversy over the clinical efficacy of the vaccine
in this population (Butler et al, 1993).

Problem Statement
Previous studies on the cost-effective of the pneumococcal polysaccharide vaccine in
people 65 years and older in the U.S. have been positive (Sisk et al, 1986; Sisk et al, 1997). The
results of these studies are limited as the efficacy of the vaccine in the prevention of pneumonia
is assumed to be equivalent to the efficacy of the vaccine in the prevention of invasive disease
(Sisk et al, 1986). Despite this major flaw and controversy over the protective efficacy of the
vaccine in the prevention of nonbacteremic pneumonia, the Advisory Committee on Immunization
Practices (ACIP) has considered lowering the universal vaccination age from 65 years to 50
years (Sisk et al, 2003).

Inconclusive results on the clinical efficacy of the vaccine in the

prevention of nonbacteremia pneumonia warrant additional studies (Simberkoff et al, 1993).

Research Objectives and Hypotheses
In an attempt to understand why such low rates of pneumococcal immunization exist
among the older adults, we must gain an understanding of the patient and provider factors that
surround the administration of the vaccine. In addition, until we gain more consistent results,
more studies are warranted on the efficacy of the vaccine against nonbacteremic pneumococcal
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infections in individuals 65 years and older. The primary objectives of this study were to assess
the incidence of pneumonia, incidence of pneumonia requiring hospitalization, and pneumonia
hospitalization costs among vaccinated and non-vaccinated Medicare beneficiaries. As a
secondary objective, we will describe the demographic characteristics of and circumstances
surrounding the administration of the pneumococcal polysaccharide vaccine. Our research
objective and major hypotheses are summarized in Table 1.
Table 1. Research Objectives: Questions and Hypotheses
Primary Research Objectives
Questions & Null Hypotheses (Ho)
#1. To assess the incidence of pneumonia in vaccinated and non-vaccinated patients
Ho: There is no difference in the incidence of pneumonia in those that are vaccinated versus
those that are not vaccinated
#2. To assess the incidence of pneumonia requiring hospitalization in vaccinated and
non-vaccinated patients
Ho: There is no difference in hospitalization rates among patients that are vaccinated versus
those that are not vaccinated
#3. To assess the hospitalization costs among the vaccinated and non-vaccinated
Ho: There is no difference in hospitalization costs among patients that are vaccinated versus
those that are not vaccinated

In the next section, we will highlight the findings of studies conducted among the elderly,
those aged at least 55 years. Because the incidence of S. pneumoniae strains vary around the
world, our review was restricted to studies conducted in the U.S. elderly population. Additionally,
because the 14-valent vaccine was replaced by the 23-valent vaccine in late 1983, we also
restricted the review to include only those studies evaluating the protective efficacy of the 23valent vaccine.

Literature Review
A Pubmed search was conducted for 1983 to January 2007 using “pneumococcal”,
“vaccine”, “randomized”, “efficacy”, “effectiveness”, “cohort studies”, “case-control studies”,
“resource utilization” and combinations of these and other Boolean search terms. So that
relevant studies on older adults would not be omitted, search restrictions did not include age.
The bibliography of a meta-analysis (Dear et al, 2006) of previous pneumococcal vaccine trials
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was also used to identify additional studies. Using the methods described, numerous studies
were identified. Studies that did not include the 23-valent pneumococcal polysaccharide vaccine
(PPV23) were excluded.
As a result, a total of eight observational studies were identified and are summarized in
the Appendix. Of the studies identified, there was one indirect cohort study (Butler et al, 1993);
two retrospective cohort studies (Jackson et al, 2003; Fisman et al, 2001); one nested casecontrol study (CDC, 2001c); three matched case-control studies (Sims et al, 1988; Shapiro et al,
1991; Farr et al, 1995); and one population-based case series (Chi et al, 2006). All but four
observational studies exclusively addressed the protective efficacy of the vaccine in older adults
aged 55 years or older (Fisman et al, 2006; Butler et al, 1993; Shapiro et al, 1991; Forrester et al,
1987). Despite enrolling children aged 2 years and greater, Shapiro et al (1991), and Butler et al
(1993) estimated vaccine efficacy for subgroups that included immunocompetent patients aged
65 to 74 years and immunocompetent patients 65 years and older, respectively. In general,
across all of the case-control studies cases, cases were identified as people with positive cultures
(CDC, 2001c; Farr et al, 1995; Shapiro et al, 1991; Sims et al, 1988). The indirect cohort study
conducted by Jackson et al (2003) drew from the population of a managed care organization
(Group Health Cooperative; Washington State). Chi et al (2006) drew from the same study
population to conduct a population-based case-series. The indirect cohort study conducted by
Butler et al (1993) analyzed national surveillance data for pneumococcal infections submitted to
the CDC by U.S. hospital laboratories. The 23-valent vaccine was used exclusively in four trials
(Sims et al, 1988; Shapiro et al, 1991; Butler et al, 1993; Farr et al, 1995). In another four trials,
patients were adminstered either the 14-valent vaccine (PPV14) or PPV23 (CDC, 2001c; Jackson
et al, 2003; Fisman et al, 2006; Chi et al, 2006).
Shapiro et al (1991) conducted a hospital-based case-control study. From 1984 to 1990,
patients from 11 hospitals with laboratory-confirmed pneumococcal infection and an indication for
pneumococcal vaccine were enrolled as cases. Cases and controls were matched 1:1 on age,
underlying illness, and site of hospitalization. The protective efficacy of the vaccine in the overall
population was 56% (95% confidence interval [CI]: 42%, 67%). The vaccine was only 21% (95%
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CI: -55%, 60%) effective in the immunocompromised patients; the protective efficacy in this
subgroup was significantly less than that in the immunocompetent subgroup which included
adults aged 55 years and older (1-OR: 61%; 95% CI: 47%, 72%). When stratified by increasing
age, the protective efficacy of the vaccine was only statistically significant for those aged 55 to 74
years. Based on these data, the authors concluded that there may be some benefit in
vaccinating the elderly, even at the extremes of ages (Shapiro et al, 1991).
Sims et al (1988) conducted a multicenter, case-control study of hospitalized older adults
55 years of age and older with pneumococcal bacteremia, meningitis, or any other
bacteriologically confirmed pneumococcal infection during a 5-year period. Patients were
excluded from the study if there was evidence of immunosuppression due to disease or iatrogenic
disease. A total of 366 patients were included in the study; their mean age was 69.5 ± 9.5 years.
After logistic regression modeling to control for confounding variables, the vaccine efficacy was
calculated to be 70% (95% CI: 37%, 86%). The authors of this study concluded that the vaccine
confers substantial protection from serious pneumococcal infections in immunocompetent elderly
(Sims et al, 1988). Another case-control study conducted by Farr et al (1995) demonstrated an
81% (95% CI: 34%, 94%) protective efficacy. The mean age of cases and controls in this study
were 52.8 ± 2.0 years and 57.7 ± 1.5 years, respectively. In an attempt to ensure that cases and
controls were equally likely to have a prior exposure to pneumococcal vaccine, the logistic
regression model matched on eight variables. To date no other case-controls has ever matched
on this number of variables. The results of this study further support the conclusions drawn by
previous studies (Farr et al, 1995).
In a nested case-control study conducted in 2001 among residents of a nursing home in
New Jersey (USA), the risk factors for pneumococcal pneumonia were evaluated (CDC, 2001c).
Cases included nine residents hospitalized with pneumonia. Controls were matched to cases in a
2:1 ratio and randomly selected from among nursing home residents without pneumonia
symptoms residing in the same wing where most of the case-patients had resided from March 1,
2001 through April 26, 2001. Median age of the cases and controls was similar; 86 years and 85
years, respectively. Pneumonia was strongly associated with failure to be vaccinated as zero of 9
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case-patients developed disease versus 9 of 18 controls (odds ratio [OR]: 0; 95% CI: 0.0, 0.7)
(CDC, 2001c). This study further underscores the importance of pneumococcal vaccination in the
elderly.
Jackson et al (2003) conducted a retrospective cohort study of elderly members of a
staff-model managed care organization, Group Health Cooperative (GHC), over a 3-year period.
The primary outcomes were hospitalization due to community-acquired pneumonia (validated by
chart review), pneumonia treated in the outpatient setting (determined from administrative data
sources), and pneumococcal bacteremia. Using multivariate Cox proportional-hazard models to
control for age, sex, nursing-home residence or nonresidence, smoking status, medical
conditions, and receipt or nonreceipt of influenza vaccine, the authors evaluated the association
between pneumococcal vaccination and risk of each outcome. Receipt of the pneumococcal
vaccine was associated with a significant reduction of pneumococcal bacteremia (hazard ratio
[HR]: 0.56; 95% CI: 0.33, 0.93) but a slightly increased risk of hospitalization for pneumonia (HR:
1.14; 95% CI: 1.02, 1.28). On the other hand, receipt of pneumococcal vaccination did not alter
the risk of outpatient pneumonia (HR: 1.04; 95% CI: 0.96, 1.13) or any cause of communityacquired pneumonia, whether or not it required hospitalization (HR: 1.07; 95% CI: 0.99, 1.14). In
another retrospective cohort study conducted by Fisman et al (2006), hospitalized vaccine
recipients with community-acquired pneumonia were less likely to die of any cause than were
individuals with no record of vaccination (OR: 0.50; 95% CI: 0.43, 0.59). In comparison to
nonvaccination, vaccination was also noted to lower the risk of respiratory failure (adjusted OR:
0.67; 95% CI: 0.59, 0.76) and other complications and reduced median length of stay by 2 days
(P value <0.001) (Fisman et al, 2006). Based on the results of these studies, pneumococcal
vaccine is effective in preventing bacteremic pneumonia; however other strategies are needed to
prevent nonbacteremic pneumonia (Fisman et al, 2006; Jackson et al, 2003).
Investigators of the CDC conducted an indirect cohort study to test their hypothesis that
pneumococcal infections occurring in vaccinated individuals should be fess frequently due to
vaccine serotypes than infections occurring in unvaccinated controls (Butler et al, 1993). Patients
aged 2 years or more who were of known vaccination status and vaccination date, who had onset
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of illness between May 1978 and April 1992 but greater than 30 days from vaccination until onset
of illness, and from whom a vial isolate from blood or cerebrospinal fluid (CSF) was received and
serotyped were included in the study. For immunocompetent adults older than 65 years, the
study demonstrated a vaccine efficacy of 70% (95% CI: 57%, 85%). The authors of this study
concluded that pneumococcal polysaccharide vaccine effectively prevents invasive disease due
to pneumococcal serotypes included in the vaccine in several patient populations for whom the
vaccine is currently recommended. They also concluded that the vaccine may provide a shorter
period of protection as well as less protective efficacy among patients immunocompromised by
certain underlying illnesses, including older age (Butler et al, 1993).
Chi et al (2006) conducted a population-based case series of community-dwelling adults
aged 65 years and older. Patients with at least 2 years of enrollment in GHC and a diagnosis of
pneumococcal bacteremia (confirmed by a positive blood culture or chart review) between 1988
and 2002 were included in the study. A total of 200 elderly patients were identified; on average
they had aged 78 years and 61% were female. Prior to the onset of bacteremia, 40% of patients
had chart-documented receipt of pneumococcal vaccination. Approximately 10% of the study
population was treated on an outpatient basis; of the remainder that was hospitalized (90%), 16%
were admitted to an intensive care unit (ICU). Of the survivors, 43% were discharged to a higher
level of care. After using a logistic regression model to control for age, sex, and pneumococcal
vaccination status, predictors of death included coronary artery disease (OR: 4.6; 95% CI: 1.4,
14.5) and immunocompromising conditions (OR: 5.0; 95% CI: 1.6, 15.7). Based on the results of
this study, there was no difference in the outcomes (ie, survival, hospital length of stay, and
discharge to a higher level of care) of patients who did and did not receive pneumococcal
vaccination (Chi et al, 2006).
Pneumococcal vaccination rates among the elderly range from 49.9% among those aged
65 to 74 years to 60.9% among those aged 75 years and older (CDC, 2001b). Controversy over
the clinical efficacy of the pneumococcal polysaccharide vaccine has been hypothesized as the
number one reason for such low vaccination rates Butler et al, 1993; Fedson et al, 1994;
Hirschmann et al, 1994). The most common manifestation of pneumococcal infection among the
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elderly is nonbacteremic pneumonia (Jackson et al, 2003). In patients with nonbacteremic
pneumonia the vaccine failed to confer protection (Jackson et al, 2003) but was associated with a
reduction in hospital LOS and death due to any cause (Fisman et al, 2006). The protective
efficacy of the vaccine in preventing invasive pneumococcal infection (ie, bacteremia, meningitis,
and infection of other normally sterile fluids) in U.S. elderly adults ranges from 61% to 75% (Sims
et al, 1988; Shapiro et al, 1991; Butler et al, 1993). In U.S. elderly patients with pneumococcal
bacteremia, there was no difference in outcomes (ie, all-cause mortality, hospitalization, and
hospital LOS) between those who did and did not receive the vaccine (Chi et al, 2006).
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CHAPTER TWO
Methods
In this retrospective cohort study, Medicare beneficiaries 65 years of age were assessed
over a 2-year period, January 2003 through December 2004 (Figure 2). By nature of the study
design, patients were selected based on their exposure status. Exposure was defined as receipt
of the 23-valent pneumococcal polysaccharide vaccine, PPV23, (identified by Current Procedural
Terminology [CPT] code 90736).

Figure 1. Study Design
Study Period

Pre Period
(0.5 Years)

Follow Up Period
(1 Year)

Enrollment Period
01/01/2003

07/01/2003

12/31/2003

12/31/2003

Medicare beneficiaries with evidence of PPV23 administration during the enrollment period (July
1, 2003 through December 31, 2003) were matched to individuals with no documented receipt of
PPV23 based on gender and the presence of any comorbidity. Only those aged 65 years of age
in 2003 were included in the analysis to reduce the risk that the comparison group had been
vaccinated prior to the enrollment period. Any comorbidity was defined as those conditions
associated with high risk for the development of pneumococcal infection as defined by ACIP
(Table 2). The study protocol was approved by the investigational review boards of the Centers
for Medicare and Medicaid Services (CMS) and the University of South Florida and is in
compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations.
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Table 2. ACIP PPV Recommendations
Comorbid Conditions of Interest: ICD-9 Codes
Alcoholism: 303.1-303.3, 303.9
Asplenia: 759.0
Cerebrospinal Leak: V45.2
Diabetes Mellitus (DM): 250, 250.0-250.9
Chronic Pulmonary Disease
Emphysema, Bronchitis, Asthma: 490-496
Pneumocomycoses due to external agent: 500-505
Chronic Liver Disease
Cirrhosis: 571.0-571.3, 571.5-571.6, 571.8, 571.9
Chronic Hepatitis: 571.4, 571.40, 571.41, 571.49
Human Immunodeficiency Virus (HIV): V07-V09, 042, 079.51-079.53
Immune Deficiency: 279.0, 279.00-279.06, 279.09, 279.1, 279.10-279.13, 279.19, 279.2, 279.3
Cardiovascular
Heart Disease: 420-429, 429.0-429.3, 429.8, 429.9
Myocardial Infarction: 410, 412
CHF: 428, 425, 402.01, 402.11, 402.91
Cerebrovascular Disease: 434, 435, 436, 437, 438
Key: ACIP – Advisory Committee on Immunization Practices

Data Source
The data source for this study was the Medicare 5% beneficiary encrypted files (BEF) for
the most recent two-year period from 2003 to 2004; available from CMS. The BEF represents a
random 5% sample of the entire Medicare population which essentially includes all U.S. residents
age 65 and older as well younger age groups who may qualify for Medicare due to a diagnosis of
end stage renal disease (ESRD) or certain disabilities. The BEF data includes Durable Medical
Equipment (DME), Inpatient Facility, Hospice, Outpatient Facility, Home Health Agency (HHA),
Skilled Nursing Facility (SNF), and Physician / Supplier (Part B) claims. This analysis is
conducted using claims from the Inpatient Facility, Outpatient Facility, and Physician / Supplier
files.

Study Population
Beneficiaries enrolled in Medicare Parts A and B between January 1, 2003 and
December 31, 2004 were included in the study. The current milestone for interventions to
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prevent disease or to screen for asymptomatic disease is age 65 years. As such, in an attempt to
assure no prior receipt of the pneumococcal vaccine, the study was further limited to patients who
were age 65 years in 2003. Beneficiaries aged less than or greater than 65 years were excluded
from the study.

Outcomes
The primary outcome was pneumonia, identified on the basis of International
Classification of Diseases, Ninth Revision; Clinical Modification (ICD-9 CM) codes (480 throught
486). The incidence rate of pneumonia was calculated as the number of new patients diagnosed
with pneumonia divided by total person-years of follow-up for all patients at risk for developing
pneumonia. The total number of patients at risk for developing pneumonia totaled 7,388 and they
were followed up for 1 year; as such, there were 7,388 persons-years of follow-up for patients at
risk for developing pneumonia. Pneumonia requiring hospitalization was also evaluated. The
incidence rate of hospitalization due to pneumonia was calculated as the number of new patients
with pneumonia requiring hospitalization (i.e., denoted as an inpatient visit in our claims data)
divided by total person-years of follow-up for patients with pneumonia. From January 1, 2004
through December 31, 2004, a total of 443 patients were diagnosed with pneumonia; thus, there
were 433 person-years of follow-up for persons at risk for pneumonia requiring hospitalization.
Beneficiaries were followed up for a total of 1 year; thus, there were a total of 7,388 patient-years
of follow-up. As a secondary objective, we also evaluated pneumonia hospitalization costs.
Mean costs were derived as the total claim payment amount for each claim of beneficiaries with
an inpatient claim for pneumonia divided by the total number of patients with an inpatient visit for
pneumonia.

Statistical Analysis
Descriptive statistics such as mean, standard deviation (SD), frequency, and percentage
were generated for demographic characteristics, comorbid conditions, and vaccine utilization
2

patterns. The frequency of categorical variables was compared using Chi-squared ( ) אor
Fisher’s exact test. Mantel-Haenszel chi-square or logit was used to estimate the relative risk
(RR) associated with vaccine exposure and outcome (ie, pneumonia and hospitalizations due to
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pneumonia). Means were compared using Proc Ttest for equal variance. The alpha level for
declaring statistical significance was P value <0.05. Data were analyzed using Statistical
Analysis Software (Version 9.1, SAS Institute, Inc., Cary, North Carolina).
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CHAPTER THREE
Baseline Characteristics
The cohort consisted of 7,388 persons who were followed up for 1 year (7,388 personyears), 3,694 (50%) received the pneumococcal vaccine during the enrollment period (July 1,
2003 through December 31, 2003). A majority (55.1%) was female, the most common
documented race was Caucasian, and nearly 50% of all patients had one or more predisposing
comorbidity (Table 4). The most common comorbidities, occurring in ≥10% of patients, were
cardiovascular disease and chronic pulmonary disease. Less than 1% of the vaccinated and
unvaccinated resided in a LTCF.
Table 3. Baseline Characteristics
Characteristic

Vaccinated
(N=3,694)

Non-vaccinated
(N=3,694)

P value

Female
Male

2,035 (50.0)
1,659 (50.0)

2,035 (50.0)
1,659 (50.0)

1.000

African American
Caucasian
Hispanic
Other

192 (5.2)
3,407 (92.2)
17 (0.46)
270 (2.12)

369 (9.99)
3,147 (85.2)
36 (0.97)
142 (3.84)

<0.001

Comorbidities, n (%)
Any Comorbidity
Alcoholism
Asplenia
Cardiovascular
Cerebrovascular
Cerebrospinal Leak
Chronic Liver Disease
Chronic Pulmonary Disease
HIV
Immune Deficiency

1,704 (46.3)
7 (0.19)
1 (0.03)
768 (20.8)
170 (4.60)
0 (0.00)
44 (1.19)
637 (17.2)
1 (0.03)
5 (0.14)

1,704 (46.1)
30 (0.81)
0 (0.00)
611 (16.5)
157 (4.25)
0 (0.00)
43 (1.16)
527 (14.3)
1 (0.03)
1 (0.03)

1.000
<0.001
0.500
<0.001
0.462
N/A
0.914
<0.004
0.500
0.094

3,681 (99.7)
13 (0.35)

3,678 (99.6)
16 (0.43)

0.577

Gender, n (%)

Race, n (%)

Resides in LTCF, n (%)
No
Yes
Key: N/A – not applicable
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Of the 3,694 patients with documented receipt of the vaccine, a majority (78.28%) was
vaccinated during a physician office visit to a non-institutional provider. Of the remainder, 0.28%
(n=103) of patients were vaccinated while at a hospital outpatient department, rural health clinic,
renal dialysis facility, outpatient rehabilitation facility, comprehensive outpatient rehabilitation
facility, community mental health center, or ambulatory surgical center. The remaining 21.52%
(n=795) were vaccinated at some other healthcare facility. The most common provider specialty
administering the vaccine was Internal Medicine (33.96%) followed by Family Practice (31.51%)
and a Public Health or Welfare Agency (11.50%). Table 4 outlines the specialty distribution for
providers administering the vaccine.
Table 4. Provider Specialty Distribution
Specialty

Frequency

Percent

Internal Medicine

1,332

33.96%

Family Practice

1,236

31.51%

Public Health or Welfare Agency

451

11.50%

Pulmonary Disease

107

2.73%

Other

357

9.13%

The recommended frequency for pneumococcal vaccination is once in a lifetime; unless
however 5 years lapse between when a patient is vaccinated for the first time and their 65

th

birthday (DHHS, 1997). Despite these recommendations, a total of 181 patients (4.9%) were
revaccinated within 1 year of their primary vaccination.

Outcomes
Pneumonia Disease Incidence
A total of 443 patients were assigned an ICD-9-CM code for pneumonia (codes 480
through 486); of which, 266 patients were previously vaccinated and 177 had no documented
receipt of prior vaccination. This equates to an incidence rate of 36.0 per 1,000 person-years for
the vaccinated and 24.0 per 1,000 person-years for the non-vaccinated. Results of the Chisquare analysis revealed a significant association between vaccination and the risk of pneumonia
(P value <0.0001). The vaccinated were 50% more likely to develop pneumonia than were the
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non-vaccinated (Adjusted RR: 1.50; 95% CI: 1.25, 1.81). The results of this analysis are
summarized in Table 5.

Pneumonia Requiring Hospitalization
Of the 443 patients diagnosed with pneumonia, approximately 67.2% (n=298) required
treatment within the hospital setting. Of the patients with pneumonia requiring hospitalization,
183 were previously vaccinated and 115 had no documented receipt of prior vaccination. The
incidence of pneumonia requiring hospitalization in the vaccinated was almost 2.0-times that of
the unvaccinated (41.3 per 100 person-years versus 26.0 per 100 person-years). Results of the
Chi-square analysis failed to reveal a significant association between vaccination and pneumonia
requiring hospitalization (P value 0.401). The results of this analysis are summarized in Table 5.
Table 5. Incidence and Risk of Pneumonia and Pneumonia Requiring Hospitalization in
Relation to Vaccination Status
Pneumonia (ICD-9-CM codes 480 – 486)
Variable
Adjusted rate*
Vaccinated
Non-vaccinated
Mantel-Haenszel relative risk (95% CI)
P value

Disease

Hospitalization

Per 1,000 person-years
36.0
24.0

Per 100 person-years
24.8
15.6

1.50 (1.25, 1.81)
<0.001

1.06 (0.93, 1.21)
0.401

*Risk ratios were adjusted for sex and the presence of any comorbidity.

Pneumonia Hospitalization Costs
Among this study population of vaccinated (n=183) and non-vaccinated (n=115)
Medicare beneficiaries aged 65 years, the vaccine was associated with significant reduction in
mean hospital costs (P value 0.004). Hospitalization due to pneumonia ranged from $2,361 to
$3,553 per admission for vaccinated patients and from $3,479 to $5,663 per admission for nonvaccinated patients and from; the average cost per admission for the vaccinated and nonvaccinated was $2,957 and $5,663, respectively. Because claim payment amounts for the nonvaccinated ranged from $0 to $90,419, we re-ran the analysis excluding those persons with claim
payment amounts of $0 (n=16, non-vaccinated persons). As a result, the minimum claim
payment amount for the non-vaccinated changed from $0 to $16 and the mean cost per hospital
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admission for the non-vaccinated increased by $343 to $6,006. The results of this analysis
remained significant (P value 0.001) and are summarized in Table 6.
Table 6. Pneumonia Hospitalization Costs in Relation to Vaccination Status
Pneumonia Hospitalization Costs
Vaccination Status

Mean (95% CI)

Range

P value

All Persons Hospitalized for Pneumonia
Vaccinated (n=183)

$2,957 ($2,307, $3,553)

$6 - $31,046

Non-vaccinated (n=115)

$5,663 ($3,479, $7,846)

$0 - $90,419

0.004

Minus Persons with Claim Payment Amounts = $0
Vaccinated (n=183)

$2,957 ($2,307, $3,553)

$6 - $31,046

Non-vaccinated (n=99)

$6,006 (3$,705 - $8,306)

$16 - $90, 419
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0.001

CHAPTER FOUR
Discussion
In this retrospective cohort study of 7,388 Medicare beneficiaries aged 65 years,
vaccinated persons were 50% more likely to develop pneumonia than were non-vaccinated
persons (P value <0.001). Despite controlling for the presence of any comorbidity, it is possible
that residual confounding influenced our estimates of association between vaccination and risk of
pneumonia. These results are not surprising as the vaccinated group was comprised of more
immunocompromised patients than the non-vaccinated group; 21% versus 17%, respectively, for
cardiovascular disease and 17% versus 14%, respectively, for chronic pulmonary disease (P
value <0.001 for both comorbidities). Similar to other studies, we assume that S. pneumoniae
was a common cause of pneumonia in this population (Jackson et al, 2003). Based on this
assumption and our presumption of residual confounding, we can not conclude from these results
that vaccination is not effective in preventing pneumococcal pneumonia. The direction of the
association between vaccination and risk of pneumonia for this study (Adjusted RR: 1.50; 95%
CI: 1.25, 1.81) is similar to the direction of the association between vaccination and outpatient
pneumonia (Adjusted HR: 1.04; 95% CI: 0.96, 1.13) found in the retrospective cohort study
conducted by Jackson et al (2003). Despite having 98% power to detect a 15% change in the
risk of outpatient pneumonia and vaccination, Jackson and colleagues failed to detect such a
decrease in risk (Jackson et al, 2003).
The results of our second analysis are consistent with the population based-case series
study conducted by Chi et al (2006), which concluded that there was no evidence that the
vaccine is associated with a reduction in the risk of hospitalization (Chi et al, 2006). In a
retrospective cohort study conducted by Jackson et al (2003), the vaccine was associated a
significant increase in risk of hospitalization for CAP; the vaccinated were 14% more like to be
hospitalized for CAP than were the non-vaccinated (Adjusted HR: 1.14: 95% CI: 1.02, 1.28)
(Jackson et al, 2006). In the same study, the vaccinated were found to be 6% more likely to be
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discharged from the hospital with a diagnosis of pneumonia than were the non-vaccinated;
however, the results of this analysis did not reach statistical significance (Adjusted HR: 1.06; 95%
CI: 0.98, 1.16) (Jackson et al, 2006). Despite there being no difference in the rate of pneumonia
requiring hospitalization among the vaccinated versus the non-vaccinated, our study suggests
that there is a difference in hospital costs.
To date, no other study has looked at pneumonia hospitalization costs among vaccinated
and non-vaccinated Medicare beneficiaries. On average, hospital admission costs for the
vaccinated Medicare beneficiaries with pneumonia were $2,705 less than hospital admission
costs for non-vaccinated beneficiaries (P value 0.004). Claim payment amounts ranged from $0
to $90,219 for the non-vaccinated and from $6 to $31,046 for the vaccinated; the upper limit of
the claim payment amount range for the non-vaccinated was nearly three-times that of the
vaccinated. This difference in magnitude may be due to the presence of outliers or longer
hospital stays. Because we feel it is impossible to be hospitalized for pneumonia and not to incur
costs, we re-ran our analysis excluding the 16 non-vaccinated persons with claim payment
amounts of $0. The vaccine was still associated with a significant reduction in hospital costs; the
difference in mean costs increased from $2,705 to $3,049 (P value <0.001).
In an attempt to understand why such low rates of pneumococcal immunization exist
among older adults, we investigated the circumstances surrounding the administration of the
vaccine to identify the provider specialties most frequently administering the vaccine and to
quantify the proportion of patients revaccinated within 1 year of primary vaccination. Based on
the results of our analysis, the most common provider specialties administering the vaccine was
Internal Medicine (33.96%) and Family Practice (31.51%). Because such a large percentage of
patients suffer from comorbid conditions of the pulmonary and cardiovascular systems,
pulmonary disease and cardiovascular disease specialists should be administering the vaccine at
much higher rates than those observed in this study; only 2.63% of the patients in our study were
administered the vaccine by a pulmonary disease specialist.

The ACIP recommended

vaccination frequency for S. pneumoniae is once in a time lifetime; revaccination is recommended
for those persons aged 65 years who received their primary vaccination ≥5 years previously. In
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our study, a total of 181 patients (4.9%) were revaccinated within 1 year of their primary
vaccination. Further investigation is warranted to distinguish true revaccination from duplicate
claims. We were not able to investigate this issue due to the limitations of our data.

Limitations
Much like other observational studies, this study is subject to the limitation of a
nonrandomized study design (Jackson et al, 2003). The primary source of these data was the
CMS administrative claims database. As such, ascertainment of medical conditions (ie,
pneumonia and other chronic medical conditions) and/or procedures (ie, pneumococcal
vaccination) is subject to some degree of misclassification as the claims data are only as good as
the person entering claims for adjudication (Jackson et al, 2003). Additionally, date variables in
the CMS administrative claims database are formatted as 8 digit numeric variables denoting
month, quarter, and year (ie, MMQQYYYY). As such, we could not further investigate
revaccination rates or the possibility of outliers among our claim payment amounts for the nonvaccinated.
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Appendix A: Studies of Pneumococcal Vaccine Effectiveness in Older Adults
Reference /
Study Dates
Sims et al, 1988*
Study Dates
Not Reported

Study Population /
Infection Type
Study Population
• Hospitalized
immunocompetent >55
yrs
Infection Type
• Invasive Infection**

Shapiro et al, 1991*
Study Dates
Not Report

Study Population
• Patients admitted to one
of 11 participating
hospitals in Connecticut,
USA
• Subgroup of Interest:
Immunocompetent 65-74
yrs

Study Design /
Vaccine Valence
Study Design
• Case Control (N=366)
 Cases, n=122
 Controls, n=244
Vaccine Valence
• PPV14 or PPV23
Study Design
• Case Control (N=2,108)
 Cases, n=1,054
 Controls, n=1,054
Vaccine Valence
• PPV14 or PPV23

Key Primary /
Secondary Endpoints
There was no
distinction between
primary and secondary
endpoints
•

Study Dates
May 1978 – April 1992

Study Population
• Patients with
pneumococcal
bacteremia and/or
meningitis at institutions
participating in the
national pneumococcal

Study Design
• Indirect cohort (N=2,827)
 Unvaccinated, n=515
 Vaccinated, n=2,322
Vaccine Valence
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Invasive Infection
OR: 0.30
1- OR: 0.70
95% CI: 0.37, 0.86

Invasive Infection**

There was no
distinction between
primary and secondary
endpoints
Vaccination Rates
• Invasive Infection**
•

Infection Type
• Invasive Infection**
Butler et al, 1993

Results

Primary
• Bacteremia and/or
Meningitis
• Protection Duration

Vaccination Rates
Cases: 13%
Controls: 20%
P value <0.001
Invasive Infection
(Immunocompetent 65-74 yrs)
OR: 0.39
1 – OR: 0.61
95% CI: 0.47, 0.72
Primary
Bacteremia and/or Meningitis
(Immunocompetent ≥65 yrs)
OR: 0.25
1- OR: 0.75
95% CI: 0.57, 0.85

Reference /
Study Dates

Study Population /
Infection Type
surveillance program
• Subgroup of Interest:
Immunocompetent ≥65
yrs

Study Design /
Vaccine Valence
• PPV14 or PPV23

Key Primary /
Secondary Endpoints

Protection Duration
(Overall Study Population)
<2 yrs: 51% (22%, 69%)
2 – 4 yrs: 54% (28%, 70%)
5 – 8 yrs: 71% (24%, 89%)
≥9 yrs: 80% (16%, 95%)

Pneumococcal Infection
Type
• Bacteremia and/or
Meningitis
Farr et al, 1995
Study Dates
January 1, 1981 –
December 31, 1987

Study Population
• Patients aged ≥2 yrs with
pneumococcal
bacteremia and chronic
illness or those aged ≥65
yrs
Infection Type
• Bacteremia

CDC, 2001c

Study Population
Residents of a nursing
home in New Jersey,
USA

•

Study Dates
April 3 – 24, 2001

Infection Type
• Bacteremic Pneumonia
Jackson et al, 2003
Study Dates

Study Population
• Members of Group
Health Cooperative in

Results

Study Design
• Case Control
 Cases, n=85
 Controls, n=152

Primary
• Bacteremia

Bacteremia
(Overall Population)
OR: 0.19
1- OR: .81
95% CI: 0.34, 0.94

Vaccine Valence
• PPV14 or PPV23
Study Design
• Nested Case Control
(N=23)
 Cases, n=9
 Controls, n=18

There was no
distinction between
primary and secondary
outcomes
•

Vaccine Valence
• PPV23
Study Design
• Retrospective Cohort
(N=47,365)
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Bacteremic Pneumonia
OR: 0
95% CI: 0.0, 0.7

Bacteremic
Pneumonia

Primary
• Hospitalization for
CAP

Primary
Hospitalization for CAP
(rate per 100,000 person yrs)

Reference /
Study Dates
March 1, 1998 –
February 28, 2001

Study Population /
Infection Type
Washington State ≥65
yrs
Pneumococcal Infection
Type
• CAP
• Pneumococcal
Bacteremia

Study Design /
Vaccine Valence
 Unvaccinated, n=21,052
 Vaccinated, n=26,313
Vaccine Valence
• PPV23

Key Primary /
Secondary Endpoints
• Outpatient
Pneumonia
• Pneumococcal
Bacteremia
Secondary
• Hospitalization with
a Pneumonia
Discharge Dx

Results
Unvaccinated: 10.4
Vaccinated: 11.8
Adjusted HR: 1.14
95% CI: 1.02, 1.28
Outpatient Pneumonia
(rate per 100,000 person yrs)
Unvaccinated: 23.2
Vaccinated: 25.7
Adjusted HR: 1.04
95% CI: 0.96, 1.13
Pneumococcal Bacteremia
(rate per 100,000 person yrs)
Unvaccinated: 0.68
Vaccinated: 0.38
Adjusted HR: 0.56
95% CI: 0.33, 0.93
Secondary
Hospitalization with a
Pneumonia Discharge Dx
(rate per 100,000 person yrs)
Unvaccinated: 18.8
Vaccinated: 19.9
Adjusted HR: 1.06
95% CI: 0.98, 1.16
All-cause Mortality
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Reference /
Study Dates

Study Population /
Infection Type

Study Design /
Vaccine Valence

Key Primary /
Secondary Endpoints

Results
(rate per 100,000 person yrs)
Unvaccinated: 50.1
Vaccinated: 42.0
Adjusted HR: 0.96
95% CI: 0.91, 1.01

Fisman et al, 2006
Study Dates
September 1999 –
December 2003

Study Population
• Adults hospitalized with
CAP
Infection Type
• CAP

Study Design
• Population-Based Case
Series (N=62,918)
Vaccine Valence
• PPV23

There was no
distinction between
primary and secondary
outcomes
All-cause mortality
Adverse Events
(other than inhospital death)
• Hospital LOS
•
•

All-cause mortality
(Overall Population)
OR: 0.29
95% CI: 0.26, 0.33
Adverse Events (other than inhospital death), OR (95% CI)
ARD: 0.67 (0.59, 0.76)
Tracheostomy: 0.49 (0.33,
0.73)
Acute renal failure: 0.55 (0.46,
0.65)
Sepsis Syndrome: 0.74 (0.61,
0.90)
Cardiac Arrest: 0.55 (0.46,
0.65)
Hospital LOS
Unvaccinated: 6.5 days
Vaccinated: 4.5 days
Unknown Status: 5.5 days
P value <0.001 for pairwise
comparisons by log rank test
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Reference /
Study Dates
Chi et al, 2006
Study Population
1988 – 2002

Study Population /
Infection Type
Study Population
• Community-dwelling
patients >65 yrs with at
least 2 yrs enrollment in
Group Health
Cooperative

Study Design /
Vaccine Valence
Study Design
• Population-Based Case
Series (N=200)
Vaccine Valence
• PPV23

Infection Type
• Pneumococcal
Bacteremia

Key Primary /
Secondary Endpoints
There was no
distinction between
primary and secondary
outcomes
• All-cause Mortality
• Hospitalization
• ICU Admission
• Hospital LOS
• Discharge to Home
Care
• Discharge to Nursing
Home

Results
All-cause Mortality
Unvaccinated: 10.0%
Vaccinated: 11.3%
P value 0.78
Hospitalization
Unvaccinated: 90.0%
Vaccinated: 88.8%
P Value 0.78
Hospital LOS
Unvaccinated: 7.4 days
Vaccinated: 5.7 days
P Value 0.11
Discharge to Home Care
Unvaccinated: 25.0%
Vaccinated: 19.7%
P Value 0.24
Discharge to Nursing Home
Unvaccinated: 19.4%
Vaccinated: 19.7%
P Value 0.24

Key: ARD – acute respiratory distress, CAP – community-acquired pneumonia, CI – confidence interval, Dx – diagnosis, HR – hazard ratio, ICU – intensive care unit, LOS – length of
stay, PPV – pneumococcal polysaccharide vaccine, OR – odds ratio, yrs – years, USA – United States of America
*Summarized from abstract as full manuscript was not available due to the date published.
**Invasive infection was defined as a diagnosis of pneumococcal pneumonia, meningitis, or any other bacteriologically confirmed pneumococcal infection.
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Appendix B: Abbreviations
ACIP – Advisory Committee on Immunization Practices
ARD – acute respiratory distress
BEF – beneficiary encrypted files
CAP – community-acquired pneumonia
CDC – Centers for Disease Control and Prevention
CI – confidence interval
CMS – Centers for Medicare and Medicaid Services
CPT - Current Procedural Terminology
DME – durable medical equipment
Dx - diagnosis
ESRD – end stage renal disease
HHA – Home Health Agency
HR – hazard ratio
ICD-9-CM - International Classification of Diseases, Ninth Revision; Clinical Modification
ICU – intensive care unit
LOS – length of stay
LTCF – long term care facility
OR – odd ratio
PPV14 – 14-valent pneumococcal polysaccharide vaccine
PPV23 – 23-valent pneumococcal polysaccharide vaccine
SNF – skilled nursing facility
yrs – years
U.S. – United States
USA – United States of America
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